BioCentury
ARTICLE | Product Development

Novavax COVID-19 vaccine potently immunogenic with room to lower dose

August 5, 2020 2:28 AM UTC

Although prime-boost administration of the likely Phase II dose of Novavax’s COVID-19 vaccine led to severe adverse events in a small proportion of Phase I volunteers, the human immunogenicity and baboon protection data suggest there’s room to lower the protein-based vaccine’s dose.

The data make Novavax at least the third COVID-19 vaccine developer to show its candidate can induce sterilizing immunity in non-human primates...



Access The Full Article

BCIQ Company Profiles

Novavax Inc.